Cargando…

Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies

BACKGROUND: Disease-modifying therapies are thought to reduce the conversion rate to secondary progressive multiple sclerosis. OBJECTIVE: To explore the rate, chronology, and contributing factors of conversion to the progressive phase in treated relapsing–remitting multiple sclerosis patients. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coret, Francisco, Pérez-Miralles, Francisco C, Gascón, Francisco, Alcalá, Carmen, Navarré, Arantxa, Bernad, Ana, Boscá, Isabel, Escutia, Matilde, Gil-Perotin, Sara, Casanova, Bonaventura
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Original Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6077906/ https://www.ncbi.nlm.nih.gov/pubmed/30090637 http://dx.doi.org/10.1177/2055217318783347

Ejemplares similares

Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis
por: Casanova, Bonaventura, et al.
Publicado: (2017)

Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
por: Tenorio-Laranga, Jofre, et al.
Publicado: (2010)

Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis
por: Gil-Perotin, Sara, et al.
Publicado: (2019)

Oligoclonal M bands and cervical spinal cord lesions predict early secondary progressive multiple sclerosis
por: Alcalá Vicente, Carmen, et al.
Publicado: (2022)

Case Report: Exacerbation of Relapses Following mRNA COVID-19 Vaccination in Multiple Sclerosis: A Case Series
por: Quintanilla-Bordás, Carlos, et al.
Publicado: (2022)

Escalation vs. Early Intense Therapy in Multiple Sclerosis
por: Casanova, Bonaventura, et al.
Publicado: (2022)

High Levels of Cerebrospinal Fluid Kappa Free Light Chains Relate to IgM Intrathecal Synthesis and Might Have Prognostic Implications in Relapsing Multiple Sclerosis
por: Castillo-Villalba, Jéssica, et al.
Publicado: (2022)

Progressive Demyelination in the Presence of Serum Myelin Oligodendrocyte Glycoprotein-IgG: A Case Report
por: Gil-Perotin, Sara, et al.
Publicado: (2018)

Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience
por: Gascón-Giménez, Francisco, et al.
Publicado: (2023)

Bypassing hazard of housekeeping genes: their evaluation in rat granule neurons treated with cerebrospinal fluid of multiple sclerosis subjects
por: Mathur, Deepali, et al.
Publicado: (2015)

Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses
por: Ramo-Tello, Cristina, et al.
Publicado: (2021)

Patient's perspective in clinical practice to assess and predict disability in multiple sclerosis
por: Gil-Perotin, S., et al.
Publicado: (2022)

Perception of stigma in patients with primary progressive multiple sclerosis
por: Pérez-Miralles, Francisco, et al.
Publicado: (2019)

Treatment of Multiple Sclerosis With Teriflunomide. Multicenter Study of Real Clinical Practice in the Valencian Community-Spain
por: Landete, Lamberto, et al.
Publicado: (2021)

Disturbed Glucose Metabolism in Rat Neurons Exposed to Cerebrospinal Fluid Obtained from Multiple Sclerosis Subjects
por: Mathur, Deepali, et al.
Publicado: (2017)

Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers
por: Muñoz, Delicias, et al.
Publicado: (2013)

Bioenergetic Failure in Rat Oligodendrocyte Progenitor Cells Treated with Cerebrospinal Fluid Derived from Multiple Sclerosis Patients
por: Mathur, Deepali, et al.
Publicado: (2017)

Potential Biomarkers Associated with Multiple Sclerosis Pathology
por: Mathur, Deepali, et al.
Publicado: (2021)

Brain Atrophy in Relapsing Optic Neuritis Is Associated With Crion Phenotype
por: Cantó, Laura Navarro, et al.
Publicado: (2019)

Factors affecting the risk of relapsing-onset and progressive-onset multiple sclerosis
por: Hedström, Anna Karin, et al.
Publicado: (2021)

Cognitive impairment in multiple sclerosis: diagnosis and monitoring
por: Meca-Lallana, Virginia, et al.
Publicado: (2021)

The Epidemiology, Treatment Patterns and Economic Burden of Different Phenotypes of Multiple Sclerosis in Italy: Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis
por: Perrone, Valentina, et al.
Publicado: (2022)

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
por: Barkhof, Frederik, et al.
Publicado: (2019)

Early red nucleus atrophy in relapse‐onset multiple sclerosis
por: Margoni, Monica, et al.
Publicado: (2020)

Brain region volumes and their relationship with disability progression and cognitive function in primary progressive multiple sclerosis
por: Pérez‐Miralles, Francisco Carlos, et al.
Publicado: (2021)

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2020)

Association of acute stress with multiple sclerosis onset and relapse in Saudi Arabia
por: AlZahrani, Anwar S., et al.
Publicado: (2019)

Perturbed Glucose Metabolism: Insights into Multiple Sclerosis Pathogenesis
por: Mathur, Deepali, et al.
Publicado: (2014)

Deciphering Multiple Sclerosis Progression
por: Meca-Lallana, Virginia, et al.
Publicado: (2021)

Beta‐interferon exposure and onset of secondary progressive multiple sclerosis
por: Zhang, T., et al.
Publicado: (2015)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008)

Seasonal variation in multiple sclerosis relapse
por: Harding, Katharine, et al.
Publicado: (2017)

Factors Involved in Relapse of Multiple Sclerosis
por: Kamel, Fatemah Omar
Publicado: (2019)

Osteopontin Is Associated with Multiple Sclerosis Relapses
por: Stampanoni Bassi, Mario, et al.
Publicado: (2023)

Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years
por: Horáková, Dana, et al.
Publicado: (2020)

Elevated sCD40L in Secondary Progressive Multiple Sclerosis in Comparison to Non-progressive Benign and Relapsing Remitting Multiple Sclerosis
por: Wu, Qi, et al.
Publicado: (2021)

Potential Role of CHI3L1+ Astrocytes in Progression in MS
por: Cubas-Núñez, Laura, et al.
Publicado: (2021)

Jacksonian seizure as the relapse symptom of multiple sclerosis
por: Najafi, Mohammad Reza, et al.
Publicado: (2013)

Lymphopenia in treatment-naive relapsing multiple sclerosis
por: Lim, Zhi Wei, et al.
Publicado: (2016)

Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8n9osl3j1s8csaaaiqo04808ul